ARGX

argenx
D

ARGX

Arincen71/100B

argenx income statement 2011–2026

4.54B USD over the last twelve months, and 4.15B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
4.54B4.15B2.19B1.23B410.75M1.08B41.24M78.46M24.57M43.69M15.47M
Revenue growth
+9.23%+89.64%+78.60%+198.56%-61.89%+2,513.28%-47.44%+219.30%-43.75%+182.33%+106.51%
Cost of revenue
444.27M450.67M227.29M117.84M29.43M580.52M0.000.000.000.000.00
Gross profit
4.09B3.70B1.96B1.11B381.32M497.28M41.24M78.46M24.57M43.69M15.47M
Gross margin
90.21%89.15%89.62%90.39%92.83%46.14%100.00%100.00%100.00%100.00%100.00%
Research and development
989.00M1.36B983.42M859.49M663.37M580.52M370.49M220.77M95.64M62.07M33.19M
Selling, general and administrative
1.37B1.36B1.06B709.54M469.92M305.52M170.55M72.15M26.33M14.93M7.37M
Operating expenses
2.76B2.65B1.98B1.53B1.10B846.02M518.86M277.35M118.20M71.20M38.00M
1.33B1.05B-21.65M-425.05M-720.34M-348.75M-477.62M-198.89M-93.63M-27.51M-22.52M
Operating income growth
+26.29%——————————
Operating margin
29.36%25.39%-0.99%-34.66%-175.37%-32.36%-1,158.06%-253.49%-381.02%-62.98%-145.55%
Interest income
137.09M163.09M138.50M92.96M24.74M3.49M5.15M8.81M4.23M197.95K64.15K
Interest expense
3.00M4.08M2.22M904.00K2.19M1.10M403.66K139.00K———
Other non-operating income
165.11M223.99M106.83M120.55M-8.97M-51.00M-127.74M22.97M18.31M-5.46M44.17K
Pretax income
1.50B1.28B85.18M-304.50M-729.31M-399.74M-605.35M-175.92M-75.32M-32.97M-22.48M
Income tax
151.12M-13.43M-747.86M-9.44M-19.72M8.52M3.10M5.29M908.26K716.22K0.00
Effective tax rate
10.10%-1.05%-877.98%————————
1.34B1.29B833.04M-295.05M-709.59M-408.27M-608.46M-181.21M-76.23M-33.68M-22.48M
Net income growth
+4.09%+55.10%—————————
Net margin
29.64%31.11%38.03%-24.06%-172.76%-37.88%-1,475.29%-230.95%-310.22%-77.10%-145.27%
Basic shares
62.46M61.30M59.86M57.17M54.38M51.08M45.41M38.62M35.98M24.61M18.82M
64.65M66.03M65.18M57.17M54.38M51.08M45.41M38.62M35.98M24.61M18.82M
Change in diluted shares
-1.94%+1.31%+14.01%+5.13%+6.47%+12.48%+17.58%+7.35%+46.18%+30.76%+19.62%
EPS (basic)
21.5621.1413.92-5.16-13.05-7.99-13.40-4.69-2.12-1.37-1.19
20.8219.6312.78-5.16-13.05-7.99-13.40-4.69-2.12-1.37-1.20
EPS growth
+6.28%+53.60%—————————
EBITDA
1.40B1.31B105.17M-192.29M-622.78M-392.78M-601.03M-173.36M-93.06M-32.45M-22.17M
EBITDA margin
30.92%31.56%4.80%-15.68%-151.62%-36.44%-1,457.30%-220.94%-378.72%-74.27%-143.29%
EBIT
1.39B1.28B87.64M-303.59M-727.12M-398.65M-604.95M-175.78M-93.63M-32.97M-22.52M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about argenx's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.